{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:38:16Z","timestamp":1764905896527,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejca.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T04:23:33Z","timestamp":1582259013000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy"],"prefix":"10.1016","volume":"129","author":[{"given":"Alice","family":"Indini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Foresti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.01.009_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2020.01.009_bib2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.009_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejca.2020.01.009_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","article-title":"Guillain-Barr\u00e9 and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejca.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10067-013-2419-8","article-title":"Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases","volume":"33","author":"Theibich","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejca.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jamaneurol.2015.2251","article-title":"Novel variant of miller Fisher syndrome occurring with tumor necrosis factor \u03b1 antagonist therapy","volume":"72","author":"Ratnarajan","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejca.2020.01.009_bib7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.ejca.2020.01.009_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ejca.2020.01.009_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.29245\/2572.942X\/2016\/4.1040","article-title":"Central nervous system toxicities of anti-cancer immune checkpoint blockade","volume":"1","author":"Blackmon","year":"2016","journal-title":"J Neurol Neuromed"},{"key":"10.1016\/j.ejca.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:10Z","timestamp":1760732770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492030023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":10,"alternative-id":["S095980492030023X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}